Serum S100B protein is associated with depressive symptoms in patients with end-stage renal disease
Authors:
- Sung Gyun KimSKSung Gyun Kim
- Hyung Jik KimHKHyung Jik Kim
- Young Rim SongYSYoung Rim Song
- 1 December 2012
- journal article
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (18) , 1573-1577
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- S100B protein in neurodegenerative disordersClinical Chemistry and Laboratory Medicine (CCLM), 2011
- S100B Protein, a Damage-Associated Molecular Pattern Protein in the Brain and Heart, and BeyondCardiovascular Psychiatry and Neurology, 2010
- Serum markers support disease-specific glial pathology in major depressionJournal of Affective Disorders, 2008
- Biological and methodological features of the measurement of S100B, a putative marker of brain injuryClinical Biochemistry, 2008
- Depression, Quality of Life and Malnutrition-Inflammation Scores in Hemodialysis PatientsAmerican Journal of Nephrology, 2008
- Screening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2007
- Depression in Patients with End-Stage Renal Disease Treated with DialysisClinical Journal of the American Society of Nephrology, 2006
- S100B and response to treatment in major depression: a pilot studyEuropean Neuropsychopharmacology, 2003
- S100B is increased in mood disorders and may be reduced by antidepressive treatmentNeuroReport, 2002
- Neurotrophic Factor S100beta in Major DepressionNeuropsychobiology, 2001